• Utility Study indicates KidneyIntelX risk assessment can address treatment ambiguity in primary care
  • Renalytix announces new data demonstrating that KidneyIntelX can be effective at monitoring SGLT2 therapeutic response and improvements in kidney health over time in adults with Type 2 diabetes


  • Renalytix partners with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine to reduce impact of kidney disease in large populations


  • Multi-Center Study finds KidneyIntelX 72% more effective than the current standard of care in identifying early-stage patients at higher risk for disease progression and failure
  • Clinical Utility Study demonstrates that primary care physicians highly likely to order KidneyIntelX to inform care decisions
  • Renalytix and Joslin Diabetes Center enter exclusive option agreement for patent filings on select additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX platform
  • KidneyIntelX demonstrates performance and informs treatment decisions in multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
  • U.S. General Services Administration grants 10-year governmentwide contract for KidneyIntelX testing